Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25471029

Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Future Oncol
Publication date
2014 Nov
First author
Palmieri G

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Palmieri G
      type
      Author
    2. name
      Buonerba C
      type
      Author
    3. name
      Ottaviano M
      type
      Author
    4. name
      Federico P
      type
      Author
    5. name
      Calabrese F
      type
      Author
    6. name
      Von Arx C
      type
      Author
    7. name
      De Maio AP
      type
      Author
    8. name
      Marino M
      type
      Author
    9. name
      Lalle M
      type
      Author
    10. name
      Montella L
      type
      Author
    11. name
      Merola C
      type
      Author
    12. name
      Milella M
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Palmieri G
      type
      Author
    2. name
      Buonerba C
      type
      Author
    3. name
      Ottaviano M
      type
      Author
    4. name
      Federico P
      type
      Author
    5. name
      Calabrese F
      type
      Author
    6. name
      Von Arx C
      type
      Author
    7. name
      De Maio AP
      type
      Author
    8. name
      Marino M
      type
      Author
    9. name
      Lalle M
      type
      Author
    10. name
      Montella L
      type
      Author
    11. name
      Merola C
      type
      Author
    12. name
      Milella M
      type
      Author
    bibliography ids
    1. nci-bib-986724b21c438ca2666261c6
    book metadata
    content sha256
    66461f3372e4a6a6269d3523b1b269c5260f5b87d854a79fba1539a4dd76c8d3
    document type
    citation
    dois
    1. 10.2217/fon.14.144
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:25471029
    immutable id
    pubmed:25471029@66461f3372e4a6a6269d3523b1b269c5260f5b87d854a79fba1539a4dd76c8d3
    journal
    abbreviation
    Future Oncol
    issn electronic
    1744-8301
    issn print
    1479-6694
    issue
    14
    name
    Future oncology (London, England)
    nlm unique id
    101256629
    pages
    2141-7
    volume
    10
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      25471029
      provenance
      batch id
      863b068fe5a07222af6a
      provider
      NCBI PubMed ESummary
      record sha256
      9d1fa1215e728944170b74cff207554f84f423c846622aaecee63cd4fbcaffbe
      response sha256
      80b1cc99e93fcfceb3e1b12ea433c615b032a2db13a615db7a6e9382c17c5034
      retrieved at
      2026-09-09T23:47:07.648963+00:00
      publication date
      display
      2014 Nov
      precision
      month
      year
      2014
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Multicenter Study
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/25471029/
      title
      Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.

      Preserved source evidence · Not medical advice